Expertise in
16
conditions

Dr. Przemyslaw W. Twardowski

Oncology | Hematology
Providence Saint Johns Medical Foundation
2121 Santa Monica Blvd, 
Santa Monica, CA 
Offers Telehealth
Expertise in
16
conditions
Providence Saint Johns Medical Foundation
2121 Santa Monica Blvd, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Przemyslaw Twardowski is an Oncologist and a Hematologist in Santa Monica, California. Dr. Twardowski is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Saint John's Health Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

PROVIDENCE SAINT JOHNS MEDICAL FOUNDATION
2121 Santa Monica Blvd, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance
A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2025
Intervention Type: Other, Drug
Study Drug: White Button Mushroom Extract
Study Phase: Phase 2
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Goserelin acetate, Leuprolide acetate
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drug: White Button Mushroom Extract
Study Phase: Phase 1
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Radiation, Procedure, Other
Study Phase: Not Applicable
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer
Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Biological, Other, Radiation
Study Phase: Phase 2
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: December 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

59 Total Publications

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2).
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2).
Journal: Prostate cancer and prostatic diseases
Published: June 25, 2024
Similar Doctors
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
2811 Wilshire Blvd, Suite 414, 
Santa Monica, CA 
 (0.6 mi)
310-552-9999
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is highly rated in 26 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
9201 W Sunset Blvd, 
West Hollywood, CA 
 (6.5 mi)
310-623-1222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Berenson is a Hematologist and an Oncologist in West Hollywood, California. Dr. Berenson is highly rated in 7 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Bone Tumor, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia, and Vertebroplasty.

Expertise in
24
conditions
Dr. Alexandra Drakaki
Hematology | Oncology
Expertise in
24
conditions
Dr. Alexandra Drakaki
Hematology | Oncology

The Regents Of The University Of California

200 Ucla Medical Plz, Suite B265, 
Los Angeles, CA 
 (3.1 mi)
310-825-0128
Languages Spoken:
English
Offers Telehealth

Alexandra Drakaki is a Hematologist and an Oncologist in Los Angeles, California. Dr. Drakaki is highly rated in 24 conditions, according to our data. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Twardowski's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile